We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00868894
First Posted: March 25, 2009
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Santen Inc.
  Purpose
To investigate safety, efficacy, and the dose-response relationship of DE-104 in lowering intraocular pressure in Japanese and Non-Japanese subjects with primary open-angle glaucoma or ocular hypertension.

Condition Intervention Phase
Open-Angle Glaucoma Ocular Hypertension Drug: DE-104 medium concentration Drug: DE-104 high concentration Drug: Placebo Drug: 0.005% latanoprost Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-masked, Placebo- and Active-controlled, Multi-Center, Dose Escalation Trial of DE-104 Ophthalmic Solution in Japanese and Non-Japanese Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

Resource links provided by NLM:


Further study details as provided by Santen Inc.:

Primary Outcome Measures:
  • To compare the safety and efficacy of two concentrations of DE-104 ophthalmic solution with placebo and 0.005% latanoprost in Japanese and Non-Japanese subjects with primary open-angle glaucoma or ocular hypertension. [ Time Frame: 15 days ]

Secondary Outcome Measures:
  • To investigate the dose-response relationship of DE-104 in lowering intraocular pressure in Japanese and Non-Japanese subjects with primary open-angle glaucoma or ocular hypertension. [ Time Frame: 15 days ]

Enrollment: 49
Study Start Date: March 2009
Study Completion Date: June 2010
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: DE-104 medium concentration
Topical ocular application
Experimental: 2 Drug: DE-104 high concentration
Topical ocular application
Placebo Comparator: 3 Drug: Placebo
Topical ocular application
Active Comparator: 4 Drug: 0.005% latanoprost
Topical ocular application

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provided signed, written informed consent.
  • 18 years of age and older.
  • Diagnosed with primary open-angle glaucoma or ocular hypertension.
  • If a subject is a female of childbearing potential she must utilize reliable contraceptive throughout the study, and must have a negative urine pregnancy test prior to enrollment into this study.

Exclusion Criteria:

  • Females who are pregnant, nursing or planning a pregnancy, or females of childbearing potential who are not using a reliable method of contraception.
  • Presence of any abnormality or significant illness that could be expected to interfere with the study.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00868894


Locations
United States, California
Artesia, California, United States, 90701
Pasadena, California, United States, 91105
San Francisco, California, United States, 94102
United States, Hawaii
Honolulu, Hawaii, United States, 96814
Kailua, Hawaii, United States, 96734
United States, New York
New York, New York, United States, 10016
Sponsors and Collaborators
Santen Inc.
  More Information

Responsible Party: Santen Inc.
ClinicalTrials.gov Identifier: NCT00868894     History of Changes
Other Study ID Numbers: 27-003
First Submitted: March 23, 2009
First Posted: March 25, 2009
Last Update Posted: October 12, 2017
Last Verified: November 2011

Additional relevant MeSH terms:
Hypertension
Glaucoma
Glaucoma, Open-Angle
Ocular Hypertension
Vascular Diseases
Cardiovascular Diseases
Eye Diseases
Ophthalmic Solutions
Latanoprost
Pharmaceutical Solutions
Antihypertensive Agents